Skip to content
Companies

3X Genetics

Long-read tests for repeat expansion genetic disorders

Raised to date

$3.2M

of $4M offered across 1 Form D filing

Still open
$840K
Investors
52
Last filed
Mar 25, 2026

About

3X Genetics is a Worcester, Massachusetts genetic diagnostics company founded in 2021 by Kevin Donahue after a seven-year diagnostic journey in his own family. It develops targeted long-read tests for repeat expansion disorders (REDs) -- genetic conditions such as Myotonic Dystrophy Type 1 that conventional sequencing struggles to resolve. Its patent-pending 3X-TGT platform measures targeted sequences directly without amplification, using AI-driven assay design plus validation to deliver faster, more precise and lower-cost tests from a saliva sample. The company runs a CLIA-certified laboratory in Manchester, New Hampshire and has raised roughly $3.16M toward a $4M seed round.

Direct, unamplified targeted long-read measurement of repeat expansion regions that standard sequencing cannot read accurately, delivered from a saliva sample and designed to drop into normal clinical workflows.

Funding

  • EquityFiled Mar 25, 2026Form D
    $3.2M/ $4M

Product

3X-TGT platform

Molecular diagnostics

A patent-pending targeted genetic testing platform that sequences difficult genomic regions directly, without amplification, to size and characterize repeat expansions.

  • Targeted long-read sequencing without amplification
  • AI-driven assay design with rigorous validation
  • Saliva-sample collection

Built for

Clinicians and hospitals ordering genetic tests for suspected repeat expansion disorders, plus biopharma companies running programs in those indications

People on file